secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvation Bio Inc. (NUVB)
CIK:        0001811063
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001193125-26-204056
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvation Bio Q1 2026 net product revenue $18.5M; net income $5.4M vs loss year ago
--------------------------------------------------------------------------------

- Net product revenue $18.5M from IBTROZI; net income $5.4M ($0.02 basic EPS) vs net loss $53.2M year ago.
- Collaboration revenue $64.7M including $58.7M upfront from Eisai; cash and securities $533.7M.
- Over 600 patients started IBTROZI since launch; majority of ~200 new Q1 patients were TKI-naïve.
- Acquired Japan rights to safusidenib from Daiichi Sankyo, gaining full global development and commercialization rights.
- Updated pooled TRUST data at AACR: mPFS 46.1 months, mDOR 49.7 months in TKI-naïve ROS1+ NSCLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811063/000119312526204056/0001193125-26-204056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811063/000119312526204056/d132166d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-204056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer